With 128 TGF-B targeted therapies in the clinic and 68 in the preclinical stage, the TGF-B field is currently being rejuvenated by novel approaches in immuno-oncology, and cutting edge research in fibrosis, autoimmune diseases, and beyond.

The TGF-B Targeted Drug Development Summit returns to San Francisco for the 4th year to deep dive into the hottest topics in the field, such as combination strategies being employed by Genentech and discovering new and predictive biomarkers from Corbus Pharmaceuticals. This meeting will support you in securing clinical success with safe and efficacious TGF-B targeted therapies.

With a program consisting of TGF-B industry leaders such as Cue Biopharma, Synthis, and Pfizer, this year promises to spotlight innovative ways biotech and large pharma companies are overcoming toxicity, translation, and proving clinical efficacy. Join us in October to celebrate the accomplishments of the TGF-B field and anticipate the future towards clinically effective and approved TGF-B targeted therapies.

URLs:

Tickets: https://go.evvnt.com/2479168-2?pid=91 

Brochure: https://go.evvnt.com/2479168-3?pid=91 

Prices:

Conference + 2 Workshops - Industry Pricing: USD 3497.00,

Conference + 2 Workshops - Academic Pricing: USD 2897.00,

Conference + 2 Workshops - Service and Solution Provider Pricing: USD 4397.00,

Conference + 1 Workshop - Industry Pricing: USD 3048.00,

Conference + 1 Workshop - Academic Pricing: USD 2548.00,

Conference + 1 Workshop - Service and Solution Provider Pricing: USD 3848.00,

Conference Only - Industry Pricing: USD 2599.00,

Conference Only - Academic Pricing: USD 2199.00,

Conference Only - Service and Solution Provider Pricing: USD 3299.00

Speakers: Alessandra Castiglioni, Senior Scientific Manager, Genentech, Anthony Conley, Associate Professor, MD Anderson Cancer Center, Anthony Maida, Chief Clinical Officer - Translational Medicine, Oncotelic Therapeutics, Daniel Doza, Scientist, Pfizer, David Horwitz, Co-Founder, General Nanotherapeutics, Deepali Sawant, Senior Principal Scientist, Amgen, Dori Thomas-Karyat, Chief Executive Officer, Synthis, Farhad Parhami, President and Chief Executive Officer, MAX BioPharma, Jack Chen, Scientific Director - IO Translational Research Group Lead, Precision Medicine, Abbvie, Jan Schnitzer, Founder, Chief Executive Officer and Institute Director, Proteogenomics Research Institute For Systems Medicine, Michael Lahn, Chief Medical Officer, iOnctura SA, Mythreye Karthikeyan, Associate Professor Molecular and Cellular Pathology, University of Alabama, Natalia Blanco, Associate Director - Immuno-Oncology, Morphic Therapeutics, Natasha Girgis, Director - Translational Pharmacology, Cue Biopharma, Rishi Bedi, Chief Executive Officer, Y-Trap, Steve Thorne, Chief Scientific Officer, KaliVir Immunotherapeutics, Tony Reid, Chief Executive Officer, EpicentRx, Vaishali Shinde, Senior Director - Translational and Clinical Assay Lead, Corbus Pharmaceuticals